/ Aurobindo Declares Growth Prospects For Next 3-4 Years ~ Ways2Capital|Stock Tips|Stock Market Tips|Intraday Stock Tips|Stock Trading Tips|NSE BSE Tips

Tuesday, 10 January 2017

The seventh largest generic company by volume in US markets, Aurobindo Pharma, has released its investor presentation to be submitted in JP Morgan Healthcare conference, starting today.

The Company has stated that it has filed 2428 and 421 formulations in Europe and the US respectively, with different regulatory authorities in the last 6 months that ended in December 2016. Company has duly put forth growth drivers for FY16-19E/20E.

Company aims at expansion of portfolio with a balanced approach through augmented growth in injectable, OTC and higher complexity products. Secondly, it would be increasing collaboration for penetration into global markets to increase its customer base.

Thirdly and most importantly, company is looking forward to establish operational efficiencies and cost leadership in API, formulation manufacturing and supply chain planning & distribution. While building a differentiated product mix, company would spend more on R&D to build Oncology Products, Hormones, Depot injections, Peptides, Inhalers, Patches, Films, Vaccines, Biosimilars and Differentiated Oral delivery products.

For Quick Trial – 8962000225 ✔
or mail us here: info@ways2capital.com
✆ - 0731-6626222 | Toll Free - 1800-3010-2007
Give a Missed Call for Free Trial - 09699997717